BRPI0910388A2 - agentes terapêutico antivirais. - Google Patents

agentes terapêutico antivirais.

Info

Publication number
BRPI0910388A2
BRPI0910388A2 BRPI0910388A BRPI0910388A BRPI0910388A2 BR PI0910388 A2 BRPI0910388 A2 BR PI0910388A2 BR PI0910388 A BRPI0910388 A BR PI0910388A BR PI0910388 A BRPI0910388 A BR PI0910388A BR PI0910388 A2 BRPI0910388 A2 BR PI0910388A2
Authority
BR
Brazil
Prior art keywords
compounds
therapeutic agents
antiviral therapeutic
antiviral
useful
Prior art date
Application number
BRPI0910388A
Other languages
English (en)
Inventor
Wu Minwan
Chand Pooran
Kotian Pravin
Satish Kumar V
S Babu Yarlagadda
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BRPI0910388A2 publication Critical patent/BRPI0910388A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/10—Internal combustion engine [ICE] based vehicles
    • Y02T10/30—Use of alternative fuels, e.g. biofuels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos antivirais, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos a presente invenção refere-se a compostos de fórmula i:como descrito aqui, bem como composições farmacêuticas compreendendo os compostos, e métodos sintéticos e intermediários que são úteis para preparar os compostos. os compostos de fórmula (i) são úteis como agentes antivirais e/ou como agentes anticâncer.
BRPI0910388A 2008-03-05 2009-03-05 agentes terapêutico antivirais. BRPI0910388A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3405308P 2008-03-05 2008-03-05
US7937008P 2008-07-09 2008-07-09
PCT/US2009/036213 WO2009111653A2 (en) 2008-03-05 2009-03-05 Antiviral therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0910388A2 true BRPI0910388A2 (pt) 2019-06-11

Family

ID=41054287

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910388A BRPI0910388A2 (pt) 2008-03-05 2009-03-05 agentes terapêutico antivirais.

Country Status (16)

Country Link
US (2) US7994139B2 (pt)
EP (1) EP2265275A2 (pt)
JP (1) JP2011525171A (pt)
KR (1) KR20100137494A (pt)
CN (1) CN102834513A (pt)
AR (1) AR071745A1 (pt)
AU (1) AU2009221770A1 (pt)
BR (1) BRPI0910388A2 (pt)
CA (1) CA2717173A1 (pt)
EA (1) EA201070988A1 (pt)
IL (1) IL207826A0 (pt)
MX (1) MX2010009646A (pt)
NZ (1) NZ588179A (pt)
PE (1) PE20091727A1 (pt)
TW (1) TW200942243A (pt)
WO (1) WO2009111653A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2114980T1 (sl) * 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
CA2685520A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
PL2898885T3 (pl) 2010-10-15 2018-04-30 Biocryst Pharmaceuticals, Inc. Pochodne pirolopirymidynowe do zastosowania w leczeniu zakażeń wirusowych
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6268656B2 (ja) * 2013-03-14 2018-01-31 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
WO2017155886A1 (en) 2016-03-06 2017-09-14 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041531A2 (en) 1999-01-13 2000-07-20 Genentech, Inc. Serine protease inhibitors
JP2002279640A (ja) 2001-03-21 2002-09-27 Ricoh Co Ltd ウォブル検出回路とその装置
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
CN1863813B (zh) * 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
JP5089395B2 (ja) 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
HRP20070436A2 (hr) 2005-02-28 2008-02-29 Genelabs Technologies Triciklički nukleozidni predlijekovi za liječenjevirusnih infekcija
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
SI2114980T1 (sl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
CA2685520A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer

Also Published As

Publication number Publication date
US20090227524A1 (en) 2009-09-10
US7994139B2 (en) 2011-08-09
TW200942243A (en) 2009-10-16
US20120142617A1 (en) 2012-06-07
PE20091727A1 (es) 2009-12-04
EP2265275A2 (en) 2010-12-29
MX2010009646A (es) 2010-09-28
NZ588179A (en) 2012-09-28
CN102834513A (zh) 2012-12-19
AU2009221770A1 (en) 2009-09-11
KR20100137494A (ko) 2010-12-30
WO2009111653A3 (en) 2011-09-22
IL207826A0 (en) 2010-12-30
AR071745A1 (es) 2010-07-14
WO2009111653A2 (en) 2009-09-11
JP2011525171A (ja) 2011-09-15
EA201070988A1 (ru) 2011-12-30
CA2717173A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
BRPI0910388A2 (pt) agentes terapêutico antivirais.
MX2019003738A (es) Compuestos antivirales.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112014026703A2 (pt) inibidores de dna-pk
BR112015015468B8 (pt) Composto, e, composição farmacêutica
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY33735A (es) Compuestos antivirales
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CO6351783A2 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
BRPI1008855B8 (pt) derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
BR112012029647A2 (pt) novos derivados de pirimidinas
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012031340A2 (pt) derivados de cianoquinolina
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES REIVINDICADAS US 61/034,053 DE 05.03.2008 E US 61/079,370 DE 09.07.2008 POIS A EXIGENCIA FORMULADA NA RPI 2515 DE 19/03/2019 NAO FOI RESPONDIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]